

Using Pediatric PROMIS (Patient Reported Outcomes Measurement Information System) to Evaluate Symptom Burden Experienced by Children with Brain Tumors


Jin-Shei Lai, PhD, OTR

Feinberg School of Medicine, Northwestern University, Chicago, IL

What is PROMIS®?

Patient-Reported Outcomes Measurement Information System®

- Supported by the NIH Blueprint/Common Fund (2004-2018)
- Now supported by HealthMeasures, the official information & distribution center for 4 NIH-supported measurement systems (PROMIS®, Neuro-QoL, NIH Toolbox®, & ASCQ-Me®)



HealthMeasures.net/PROMIS

HealthMeasures consists of four precise, flexible, and comprehensive measurement systems that assess physical, mental, and social health, symptoms, well-being and life satisfaction; along with sensory, motor, and cognitive function.





What is PROMIS®?

- Measures used to evaluate and monitor physical, mental, and social health (adult & pediatric)
- More than 50 research protocols aligned with evolving PROMIS standards
- More than 60,000 people contributed data
 - Adults: **1,402 questions** populating >80 “item banks”
 - Children: **462 questions** populating >20 item banks
- English, Spanish, Dutch, German, and other languages emerging
- Universal concepts; expandable to specific issues
- International PROMIS working group
- Began as a US NIH effort to standardize patient reported outcomes for clinical research
- Expanded to clinical practice, quality measurement, population health, and international adoption

Essential Components of PROMIS

DOMAIN

The feeling, function, or perception you wish to measure

Cuts across different diseases and settings. E.g., physical function, depressive symptoms



ITEM BANK

Collection of items that each measure the same domain

Used to create different measure types, all producing a score on the same metric

Cuts across different diseases and facilities – much needed for patients with rare diseases such as children with brain tumors



Children with Brain Tumors

- Children with a brain tumor are vulnerable to experiencing moderate or severe adverse events, which lead to poor health-related quality of life.
- It is challenging to evaluate comparative effectiveness with this population because
 - Brain tumors are both uncommon and diverse.
 - The functional impact of brain tumors and the range of surgical and treatment effects can vary based on characteristics of tumors such as location, size, and type.
- By focusing on common HRQOL domains, PROMIS offers an opportunity to address this deficit.
 - developed using item response theory models, which enables computerized adaptive tests (CATs)
 - scores are reported using T-score metric centered on the norming sample.

Study 1: Assess HRQOL of children with brain tumor using the PROMIS measures of Anxiety, Depression, Fatigue, Mobility, Upper extremity function, Peer relationships and Cognition.

Sample

- N=230; mean age was 14.1 (SD=3.7; 7-22 years); 52% male; 76% white; 84% were newly diagnosed.
- 95% attending school
 - 49% mainstream classroom without receiving any form of individualized educational programs (e.g., special education classroom within a regular school or special education school)
- Average years since diagnosis was 4.1 (SD=4.5)
 - The most common histology was astrocytic tumors (grades 1-4; 28.3%), followed by medulloblastoma (20%) and glial tumors (12.7%);
 - 21.7% had one or more lesions in the posterior fossa, 10.9% in the thalamus and 10.4% in the brain stem.
- Average years since last treatment was 2.6 (SD=3.4);
 - 73.8% received surgery, 74.1% chemotherapy, 56.8% radiation (41.9% received proton therapy), and 34.1% received all three modes of therapy.

Measures


- Child
 - PROMIS (computerized adaptive testing, CAT): Anxiety, Depression, Fatigue, Mobility, Upper extremity function, Peer relationships
 - 10-item PROMIS Cognition short-form (a.k.a., pediatric perceived cognitive function item bank, pedsPCF).
 - Symptom Distress Scale
 - Getting around, tired, feeling miserable , sleep, appetite & cognition
- Parent
 - Proxy versions

Results – versus SDS


	SDS - Physical		SDS - Fatigue		SDS - Emotion		SDS - Sleep		SDS - Appetite		SDS - Cognition	
	F-value	p	F-value	p	F-value	p	F-value	p	F-value	p	F-value	p
Compared to the Child-rated Symptom Distress Scale (SDS)												
Anxiety	9.91	<.0001	9.93	<.0001	8.78	<.0001	3.69	0.0132	3.98	0.0091	9.71	<.0001
Depression	11.14	<.0001	9.45	<.0001	9.08	<.0001	5.83	0.0008	4.53	0.0044	7.93	<.0001
Fatigue	20.38	<.0001	25.00	<.0001	8.13	<.0001	11.94	<.0001	16.37	<.0001	23.32	<.0001
Mobility	23.89	<.0001	7.33	0.0001	4.53	0.0043	5.15	0.0019	8.05	<.0001	9.28	<.0001
Upper Extremity	10.71	<.0001	5.17	0.0019	1.88	0.1348	0.89	0.4469	5.12	0.0020	3.27	0.0226
Peer Relationships	1.91	0.1295	5.13	0.0021	3.25	0.0235	1.27	0.2864	2.40	0.0694	5.10	0.0022
Cognition	4.81	0.0030	12.73	<.0001	4.65	0.0037	7.09	0.0002	11.74	<.0001	15.70	<.0001
Compared to the Parent rated Symptom Distress Scale (SDS)												
Anxiety	1.52	0.2121	5.71	0.0010	8.07	<.0001	1.91	0.1303	2.77	0.0441	9.52	<.0001
Depression	3.85	0.0110	10.25	<.0001	14.16	<.0001	3.23	0.0245	10.52	<.0001	11.01	<.0001
Fatigue	8.27	<.0001	16.29	<.0001	11.04	<.0001	4.58	0.0042	13.17	<.0001	12.72	<.0001
Mobility	16.06	<.0001	6.20	0.0005	5.23	0.0018	1.67	0.1757	4.34	0.0057	5.18	0.0019
Upper Extremity	16.18	<.0001	4.84	0.0031	4.25	0.0065	0.63	0.5998	3.04	0.0309	3.50	0.0171
Peer Relationships	1.91	0.1310	2.43	0.0679	4.98	0.0026	5.03	0.0025	1.13	0.3386	2.39	0.0720
Cognition	2.12	0.0994	6.38	0.0004	3.28	0.0225	3.45	0.0180	3.75	0.0122	12.50	<.0001

Planned analyses


Specifically. . . versus SDS-Physical:




Specifically. . . versus SDS-Fatigue:




Specifically . . . versus SDS-Emotion:




Specifically. . . versus SDS-Sleep:



Specifically. . . versus SDS-Appetite:



Specifically. . . versus SDS-Cognition:



PROMIS vs. clinical variables, educational programs and parent-rated child's HRQOL

	Parent-rated QOL		Karnofsky Performance Rating		Educational Program ^a		Time since last radiation ^b		Time since last chemotherapy ^b		Treatment modalities & time since last treatment ^b	
	F	p	F	p	F	p	F	p	F	p	F	p
<i>Higher scores represents <u>worse</u> symptomatic</i>												
Anxiety	4.83	0.001**	1.98	0.142	0.17	0.681	0.31	0.733	4.18	0.017*	0.91	0.457
Depression	8.04	<0.0001**	1.38	0.254	0.34	0.563	1.46	0.235	2.05	0.132	1.52	0.199
Fatigue	14.29	<0.0001**	5.43	0.005**	4.6	0.034*	2.73	0.068	1.3	0.274	3.03	0.019*
<i>Higher scores represents <u>better</u> functioning</i>												
Mobility	8.15	<0.0001**	18.99	<.0001**	3.12	0.079	4.44	0.013*	3.38	0.036*	3.26	0.013*
Upper Extremity Function	4.11	0.004**	14.4	<.0001**	3.38	0.068	4.89	0.009**	6.45	0.002**	3.4	0.011*
Peer Relationships	4.17	0.003**	0.87	0.422	1.44	0.233	1.92	0.150	2.53	0.083	1.78	0.136
Cognition	6.35	<0.0001**	2.61	0.077	25.29	<.0001**	0.04	0.957	0.69	0.505	0.36	0.838

a. "Regular classroom w/o any forms of IEP" vs. "received any forms of IEP or special education"

b. "never received tx" vs. "within 1 year" vs. "> 1 year"

Conclusions

- All PROMIS measures were significantly associated with Symptom Distress Scale reported by patients and parents
- Treatment, time since treatment, parent-rated QOL, educational program and performance ratings were associated with HRQOL
 - Domain dependent

Study 2:

*Using Pediatric PROMIS to Evaluate Changes of the
Symptom Burden Over Time*

Objectives

Monitoring symptom burden reported by patients and parents using pediatric PROMIS *Anxiety, Depressive Symptoms, Fatigue, Mobility, Upper Extremity Function, and Peer Relationships* CATs, and *Cognition* brief, fixed-form over 12 months.

- Patterns of PRO changes reported by patients and their parents as well as factors associated with these patterns.
- Correlation between patient- and parent-reported patient symptom burden.
- Whether symptom burden reported by patients and parents predicted patient survival rate.

Sample (N=289)

• Patient

- age: 12.4 yrs (range: 5-22; SD=4.7); 54.5% male; 78.6% white
- Years since recent tx: 0.39 (SD=1.2)

• Parent

- age: 43.0 yrs (SD=7.0); 17.4% male


		All patients (N=289)	Patients with vs. without 12- month Follow-up		
			w/o (n=150)	With (n=139)	
Does your child go to school?	Yes	93.0	90.8	96.0	0.098
Type of classroom attending	Mainstream classroom, no IEP	49.6	50.0	48.3	0.432
	Mainstream classroom, with IEP	35.3	35.6	35.6	
	Special education classroom within a regular school	7.1	5.9	8.5	
	Special education school	1.3	2.5	0.0	
	Other	6.7	5.9	7.6	
Histology	Low grade glioma	23.5	25.7	21.7	0.044
	Medulloblastoma & other embryonal tumors	22.8	18.9	26.8	
	Glioneuronal tumor	11.1	5.4	16.7	
	Ependymoma	7.3	6.8	8.0	
	Germinoma	6.9	6.1	7.3	
	High grade glioma	5.5	7.4	3.6	
Current Status of Tumor	Initial diagnosis only	86.3	81.5	91.3	0.017
	Recurrent	13.7	18.5	8.7	
Treatments received	none	4.5	4.1	5.1	0.222
	1 of 3 possible treatments	24.2	27.7	19.6	
	2 of 3 possible treatments	33.2	35.1	31.9	
	Chemo+radiation+surgery	38.1	33.1	43.5	
Treatments	Radiation				0.019
		No radiation	39.5	39.2	39.9
		<=1 year	29.4	35.8	22.5
		> 1 year	31.1	25.0	37.7
	Chemotherapy (missing=6)				<0.001
		No chemotherapy	25.5	34.7	15.4
		<=1 year	37.8	38.1	37.5
		> 1 year	36.7	27.2	47.1
	Surgery (missing n=5)				0.866
		No surgery	28.9	28.4	29.2
		<=1 year	21.3	22.3	19.7
		> 1 year	49.8	49.3	51.1
Type of radiation received	Photon	44.7	51.1	38.8	0.271
	Proton	52.9	46.6	58.8	
	Both photon and proton	2.4	2.3	2.5	
Years since last treatment	<= 1 year	83.9	84.1	83.5	0.886
	> 1 year	16.1	15.9	16.5	

Results


- **Linear mixed-effects models** - symptom changes over time at the group level
 - Patient-reported Cognition ($t=-2.11$, $p=0.037$) & parent-reported Anxiety ($t=2.18$, $p=0.0333$) got significantly worse over time
- **Cox proportional hazards model** – survival analysis
 - 24 deaths
 - Patient-reported Mobility (hazard ratio=0.725, $p=0.011$) and Upper Extremity Function (HR =0.703, $p=0.006$) predicted better survival.
 - Longer time since diagnosis and higher performance rating were also predictive of survival.
- **Latent class growth analysis** (LCGA) to investigate patterns of symptoms change over time at the individual level. Numbers of classes within each domain
 - ranged 2 and 5 for patients;
 - ranged 2 and 3 for parents across domains.

Anxiety

PARENT




PATIENT




Correlation between change scores of parents and patients: $r = 0.421$, $p=0.0819$

Depressive Symptoms

PARENT




PATIENT




Correlation between change scores of parents and patients: $r = 0.708$, $p = 0.0005$

Fatigue

PARENT




PATIENT




Correlation between change scores of parents and patients: $r = 0.49$, $p = 0.0150$

Mobility

PARENT




PATIENT




Correlation between change scores of parents and patients: $r = 0.44$, $p=0.0355$

Upper Extremity Function

PARENT




PATIENT




Correlation between change scores of parents and patients: $r = 0.46$, $p=0.036$

Peer Relationships

PARENT




PATIENT




Correlation between change scores of parents and patients: $r = 0.183$, $p=0.4685$

Cognition

PARENT



PATIENT



Correlation between change score of parents and patients: $r = 0.119$, $p = 0.3557$

Predictors of Pattern (Class) Membership

Domain		number of classes ^a	Sample n (by class)	Marital status	Gender (child)	IEP	Parent rated QOL	Initial dx or recurrent	Number of tx received	Length (chemo)	Length (radiation)	PSR	Age (parent)	Age (child)	Years since dx	Years since last tx
Anxiety	child	2 ^a	4 ^a ; 68; 108		*		***								*	
Depression	child	2	88; 95				***			*	*				**	
Fatigue	child	4	73;63;54;5			**	***		**			**		*		
Mobility	child	1 ^a	2 ^a ;189													
UE	child	5	17;96;35;26;13				*	*	*	**	*	**	*	***	***	**
Peer	child	1 ^a	174; 4 ^a					*								
Cognition	child	2	95;106	*		***	***									
Anxiety	parent	1 ^a	4 ^a ; 125													
Depression	parent	2	77; 54				**									**
Fatigue	parent	2	96;38				***					*				
Mobility	parent	3	97; 29; 7		*	*	***					***		**		
UE	parent	2	34; 97			**	***					**	***	***		*
Peer	parent	2	70; 59				*									
Cognition	parent	1 ^a	259; 2 ^a													

* p<0.05; ** p<0.01; *** p<0.001

UE=Upper Extremity Function; Peer= Peer Relationships; Dx=diagnosis; Tx=treatment

a. A class with a sample size less than 5 was considered trivial and not meaningful.

Conclusions

- Linear mixed effects models showed declined patient-reported Cognition and parent-reported Anxiety over time.
- Patient-reported Mobility and Upper Extremity Function predicted patients' survival.
 - Small sample size (death n=24).
- At the individual level, patients and parents showed different patterns of changed PROMIS scores over time across all domains, except *depressive symptoms*.
 - Significant factors differentiating class membership were identified, which were domain specific.
 - Different predictors were found between parents and patients

Study 3:

*Association between the pediatric PROMIS Cognition and
Leukoencephalopathy of Children with Brain Tumors*


Leukoencephalopathy Grades

Grade	Criteria
0	normal, injury not perceived
1	<ul style="list-style-type: none">• mild generalized white matter signal abnormality;• minimal or mild generalized volume loss; or• signal abnormality/damage limited to 1 lobe of involvement.
2	<ul style="list-style-type: none">• moderate generalized white matter signal abnormality;• moderate generalized volume loss; or• signal abnormality/damage limited to 2 lobes of involvement.
3	<ul style="list-style-type: none">• severe generalized white matter signal abnormality;• severe diffuse volume loss; or• signal abnormality/damage involving at least 3 lobes
4	<ul style="list-style-type: none">• near complete loss of the white matter volume; or• complete infiltration of the white matter by signal abnormality within the entire hemisphere

Leukoencephalopathy grade was based on white matter damage and degree of deep white matter volume loss shown on MRI

PedsPCF Scores (in T-score)


$F=4.14, p=0.0084$



	grade=0 (n=36)	grade=1 (n=27)	grade=2 (n=22)	grade=3 or 4 (n=14)
PedsPCF Mean	52.17	48.03	47.26	44.12

n = 99; a subsample from the study 1

Mean comparisons of individual pedsPCF items



Study 4: It is feasible to administer CAT in pediatric neuro-oncology clinics?

Results: Time and # of items to complete CAT

Itm bank	Time (SD) ^a	Number of items administered		
		Mean (SD) ^b	Min	Max
Anxiety	1.38 (1.69)	9.7 (2.9)	5	13
Fatigue	2.01 (3.96)	8.7 (2.8)	5	13
Mobility	1.46 (0.98)	8.1 (3.3)	5	13
Upper Extremity	1.3 (0.97)	10.4 (2.7)	5	13
Depression	1.31 (2.46)	8.3 (3.4)	5	13
Peer relationship	1.49 (1.95)	8.1 (3.2)	5	15


a. Time to complete CAT, in minutes

b. Number of CAT items administered

(Lai et al, 2017)


Study 5: (Minimally) important differences

The estimated important differences (IDs) for parent-rated T-scores were: Anxiety 3-7 points, Depression, 3.5-6.5 points, Fatigue 4.5-7.5 points, Mobility 4-6 points, Peer Relationships 3-5 points, Upper Extremity Function 4-7.5 points, and Cognition 2.5 - 4.5 points.



Symbols in figure represent minimum, 1st quartile, median, 3rd quartile, and maximum values for the list of included cross-sectional and longitudinal anchor-based differences


The estimated important differences (IDs) for child-rated T-scores were: Anxiety 4-6 points, Depression, 4-5 points, Fatigue 4.5-6.5 points, Mobility 3-6.5 points, Upper Extremity 2.5-8 points, and Cognition 2.5 - 5.5 points. None of the anchor-based analyses for child-rated Peer Relationships met the criteria for inclusion.




Symbols in figure represent minimum, 1st quartile, median, 3rd quartile, and maximum values for the list of included cross-sectional and longitudinal anchor-based differences

Children with other chronic conditions such as NF1-associated plexiform neurofibromas

QOL vs. General Population Norms (mean=50 SD=10)



QOL vs. General Population Norms (mean=50 SD=10)



v.s. PROMIS Global Health

	Health	Quality of life	Physical health	Mental health	Feel really sad	Have fun with friends	Listen to child's ideas	Get tired easily	Trouble sleeping when Having pain
Anxiety	***	***	***	***	***	***	***	***	***
Depressive symptom	***	***	***	***	***	***	***	***	***
Fatigue	***	***	***	***	***	***	***	***	***
Stigma	***	***	***	***	***	***	***	***	***
Pain interference	***	***	***	***	***	***	***	***	***
Psychological Stress Experiences	***	***	***	***	***	***	***	***	***
Meaning and Purpose	***	***	***	***	***	***	***	*	***
Mobility	***	***	***	***	***	***	***	***	***
Peer relationships	***	***	***	***	***	***	***	***	***
Positive Affect & Well-Being	**	***	***	***	***	***	***	**	***
Upper extremity function	***	***	***	***	***	***	***	***	***

(ANOVA) *** p<0.001; ** p<0.01; * 0<0.05

v.s. Demographic & Clinical Variables

	Gender	family w/ NF1 besides your child	chronic itch	Pain	age at diagnosis	# of café-au- lait spots	# of plexiform neurofibroma
Anxiety	ns	<.0001	ns	<.0001	0.0004	ns	ns
Depressive symptom	ns	<.0001	ns	<.0001	<.0001	ns	0.0097
Fatigue	ns	<.0001	ns	<.0001	0.0013	ns	0.0126
Pain	0.0023	<.0001	ns	<.0001	0.0001	ns	ns
Stigma	0.0123	<.0001	ns	<.0001	0.0118	ns	ns
Psychological Stress Experiences	ns	<.0001	ns	<.0001	0.0003	ns	ns
Meaning and Purpose	0.0018	0.0249	ns	<.0001	<.0001	0.031	ns
Mobility	0.0011	<.0001	ns	<.0001	<.0001	0.0151	ns
Peer relationships	ns	0.0232	0.0468	0.0022	ns	ns	ns
Positive Affect & Well-Being	ns	0.0001	ns	0.0033	0.0154	ns	ns
Upper extremity function	0.0017	<.0001	ns	<.0001	<.0001	0.0134	ns

Age at diagnosis: “10-17 years old” vs. “5-9 years old” vs. “Under 5 years old”

of café-au-lait spots: “No” vs. “Yes: ≤ 6” vs. “Yes: 6-20 (inclusive)” vs. “Yes: > 20”

of plexiform neurofibroma(s): “No” vs. “Yes: just one” vs. “Yes: 1-5” vs. “Yes: 5 or more”


Conclusions

1. Empirical evidences support pediatric PROMIS is a valid measurement system to evaluate symptom burden/health-related quality of life on children with brain tumors.
2. Symptom-based measurement systems can be used on children with various conditions who experience same symptoms such as fatigue, depression etc.
3. National based norms -- common reference group
 - Particularly important for children with rare diseases
 - Core set items + condition specific items
4. The need of individualized, tailored assessment such as PROMIS CATs when monitoring patients' HRQOL across the disease continuum
 - ~ 2 min to complete each CAT – *individualized & tailored*
 - PROMIS is available in Epic 2017 and newer versions – *feasible in clinics*
 - Link to adult measures – *across the lifespan*

Using Perceived Stigma as an Example


Core Stigma Item Set + Condition Specific Items

Make it possible to compare stigma perceived between patients with stroke vs. skin condition without losing the sensitivity to capture stigma resulted from each condition



core + condition specific items --
capturing unique condition/disease experiences

Perceived Stigma across Conditions



Acknowledgement

This study was supported by the National Cancer Institute
(R01CA174452; PI: Jin-Shei Lai)

js-lai@northwestern.edu

<http://www.healthmeasures.net/>



HealthMeasures
TRANSFORMING HOW HEALTH IS MEASURED



NeuroQoL

ASCQ-Me™
Adult Sickle Cell Quality of Life Measurement Information System

